KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.

Aurore Perrot, Jérôme Lambert, Cyrille Hulin, Andrea Pieragostini, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre-Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mohamad Mohty, Xavier Leleu, Salomon Manier, Clara Mariette, Carine Chaleteix, Thorsten Braun, Bernard De Prijck, Hervé Avet-Loiseau, Jean-Yves Mary, Jill Corre, Philippe Moreau, Cyrille Touzeau, MIDAS Study Group

N Engl J Med 393(5) 425-437

PMID40459097
PMCIDPMC13292240
DOI10.1056/NEJMoa2505133
发表日期2025-06-03
入排依据:The trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original report. However, it is excluded because the primary endpoint is MRD-negative status (a response rate), not a time-to-event efficacy endpoint. No time-to-event endpoint (e.g., OS, PFS) or associated statistics (Kaplan-Meier, HR) are reported in the abstract.
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell transplantation (ASCT) may be useful. METHODS: In this phase 3 trial, we randomly assigned transplantation-eligible patients with newly diagnosed myeloma who had completed induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) to receive consolidation therapy according to their MRD status. Patients who were MRD-negative at 10-5 sensitivity (i.e., <1 cancer cell per 100,000 normal cells, as assessed by next-generation sequencing) were assigned to undergo ASCT and receive Isa-KRd for two cycles (ASCT group) or to receive Isa-KRd for six cycles (Isa-KRd group). Patients who were MRD-positive at 10-5 sensitivity were assigned to undergo tandem ASCT (two ASCTs within a short period; tandem ASCT group) or to undergo ASCT and receive Isa-KRd for two cycles (single ASCT group). The primary end point was an MRD-negative status at 10-6 sensitivity before maintenance therapy. RESULTS: Among 485 patients who were MRD-negative at 10-5 sensitivity after induction, a premaintenance MRD-negative status at 10-6 sensitivity occurred in 86% in the ASCT group and in 84% in the Isa-KRd group (adjusted relative risk, 1.02; 95% confidence interval [CI], 0.95 to 1.10; P = 0.64). Among 233 patients who were MRD-positive at 10-5 sensitivity after induction, a premaintenance MRD-negative status at 10-6 sensitivity occurred in 32% in the tandem ASCT group and in 40% in the single ASCT group (adjusted relative risk, 0.82; 95% CI, 0.58 to 1.15; P = 0.31); 15% of the patients in the tandem ASCT group did not undergo a second ASCT. During consolidation, disease progression occurred in 5 patients and death unrelated to disease progression occurred in 2 patients - all were in the Isa-KRd or tandem ASCT groups. No new safety signals were observed. The median follow-up was 16.8 months in the ASCT and Isa-KRd groups and 16.3 months in the tandem ASCT and single ASCT groups. CONCLUSIONS: Among patients who were MRD-negative at 10-5 sensitivity after induction, the percentage with a premaintenance MRD-negative status at 10-6 sensitivity was not significantly higher with ASCT than with Isa-KRd. Among patients who were MRD-positive status at 10-5 sensitivity after induction, the percentage with a premaintenance MRD-negative status at 10-6 sensitivity was not significantly higher with tandem ASCT than with single ASCT. (Funded by Intergroupe Francophone du Myélome and others; MIDAS ClinicalTrials.gov number, NCT04934475.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Enrollment, Randomization, and Follow-up. All the patients received induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for six cycles. Patients with a postinduction minimal residual disease (MRD)–negative status at 10 −5 sensitivity (i.e., <1 cancer cell per 100,000 normal cells, as assessed by next-generation sequencing) were randomly assigned to undergo autologous stem-cell transplantation (ASCT) and receive Isa-KRd for two cycles (ASCT group) or to receive Isa-KRd for six more cycles (Isa-KRd group) as consolidation therapy. Patients with a postinduction MRD-positive status at 10 −5 sensitivity (i.e., ≥1 cancer cell per 100,000) were randomly assigned to undergo tandem ASCT (two ASCTs within a short period; tandem ASCT group) or to undergo ASCT and receive Isa-KRd for two cycles (single ASCT group) as consolidation therapy.
非 KM Figure
Figure 2Figure 2.. MRD-Negative Status after Induction Therapy and before Maintenance Therapy. Panel A shows the percentages of patients with an MRD-negative status at 10 −6 sensitivity (i.e., <1 cancer cell per million normal cells) at the end of induction and before the start of maintenance therapy according to trial group. Panel B shows Sankey diagrams of the changes in MRD status at 10 −6 sensitivity between the visit at the end of induction and the visit before the start of maintenance therapy in the ASCT and Isa-KRd groups. Data are for the subset of patients (224 in the ASCT group and 228 in the Isa-KRd group) who had available data on MRD status from the visit before the start of maintenance therapy or who had disease progression or died during the consolidation phase. MRD 10 −6 or higher indicates the presence of at least 1 cancer cell per million normal cells, and MRD less than 10 −6 the presence of less than 1 cancer cell per million normal cells.
非 KM Figure
Figure 3Figure 3. (facing page). Adverse Events (Safety Population). Panel A shows the frequency and relative risk of grade 3 or higher adverse events that occurred in at least 1% of the patients in the ASCT or Isa-KRd group. Panel B shows the frequency and relative risk of grade 3 or higher adverse events that occurred in at least 1% of the patients in the tandem ASCT or single ASCT group. The safety population included all the patients who received at least one dose of induction therapy. Adverse events were coded according to the Medical Dictionary for Regulatory Activities, version 24.1. Covid-19 denotes coronavirus disease 2019, and GI gastrointestinal.
非 KM Figure